Skip to main content

Receptor Targeting for Tumor Localisation and Therapy with Radiopeptides

Buy Article:

$55.00 plus tax (Refund Policy)

Receptor targeting with radiolabeled peptides has become very important in nuclear oncology in the past few years. The most frequently used peptides in the clinic are analogs of somatostatin (SRIF), e.g. OctreoScan, which contain chelators for the radioisotopes 111 In, 86Y, 90 Y, 67Ga, 68Ga and 64Cu or for 99m Tc and 188Re. and were labelled with the halogens 123I and 18F. Radiolabeled analogs of a-melanocyte-stimulating hormone (a-MSH), neurotensin, vasoactive intestinal peptide (VIP), bombesin (BN), substance P (SP) and gastrin/cholecystokinin (CCK) are also being developed, evaluated in vitro and in vivo and tested for clinical application. This review focuses on the expression in tumors and the regulation of receptors for these neuropeptides as well as the development of novel chelator-peptide conjugates suitable for in vivo scintigraphy or internal radiotherapy. The state of the art of radiopeptide pharmaceuticals is illustrated with four SRIF analogs, modified with the macrocyclic chelator 1, 4, 7, 10-tetraazacyclododecane- 1, 4, 7, 10-tetraacetic acid (DOTA) (D-Phe 1 )-octreotide (DOTAOC), [D-Phe 1 , Tyr 3 )-octreotide (DOTATOC), vapreotide (DOTAVAP) and lanreotide (DOTALAN). DOTA is almost a universal chelator capable of strongly encapsulating hard metals such as 111 In and 67 Ga for Single Photon Emission Tomography (SPET), 68 Ga, 86 Y and 64 Cu for Positron Emission Tomography (PET) as well as 90 Y for receptor-mediated radionuclide therapy and radiolanthanides which exhibit different interesting decay schemes. From biodistribution studies in experimental animals and from clinical data it is concluded that DOTATOC is currently the most suitable SRIF radiopeptide with the best potential in the clinic.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: D phe 1 octerotide DOTAOC D Phe1 Tyr3; bifunctional chelating BFCs; bombesin; cholecystokinin B gastrin; diethylenetriaminepentacetic acid DTPA; lanreodtide DOTALAN; melanocyte stimulating hormone MSH; melanocyte stimulating hormonev; neurotensin; positron emission tomography PET; radioiodiantion fluorination; radiopeptides; subtance P; tetraazacyclododecane 1 4 7 10 tetraacetic acid DO; vapreotide DITAVAP; vasoactive; vasoactive intestinal peptide

Document Type: Review Article

Publication date: 2000-09-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more